GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Diversity-Oriented Synthesis of Cyclic Azapeptides by A<sup>3</sup> -Macrocyclization Provides High-Affinity CD36-Modulating Peptidomimetics.
Zhang. Jinqiang J; Mulumba. Mukandila M; Ong. Huy H; Lubell. William D WD
Key Findings
- A novel A³‑macrocyclization chemistry enables the synthesis of diverse cyclic azapeptides, including GHRP‑6 analogs.
- Certain cyclic GHRP‑6 analogs show unusually high affinity for the CD36 receptor.
- These CD36‑binding analogs reduce nitric oxide and pro‑inflammatory cytokine/chemokine production in macrophage assays.
Practical Outcomes
- The main takeaway is that modified, cyclic forms of GHRP‑6 might have anti‑inflammatory properties via CD36, but they are still early‑stage research tools. No dosing or safety data are available, so they are not ready for self‑experimentation or protocol changes.
Summary
Scientists developed a new way to make ring‑shaped versions of the peptide GHRP‑6. Some of these circular analogs stick strongly to a protein called CD36 and can dampen inflammation in lab immune cells, but they have not been tested in people.
Abstract
Macrocyclization has enabled the use of peptides in drug discovery creating a need for methods to synthesize diverse peptide macrocycles. Azapeptides have advanced to clinically used drugs, however, few cyclic azapeptides have been studied. A multiple component "A<sup>3</sup> -macrocyclization" strategy is described for the preparation of diverse cyclic azapeptides and is demonstrated by the synthesis of 15 growth hormone releasing hormone-6 (GHRP-6) analogs. Certain cyclic aza-GHRP-6 analogs exhibited unprecedented affinity for the CD36 receptor, and capacity to modulate Toll-like receptor agonist-induced overproduction of nitric oxide, and reduce pro-inflammatory cytokine and chemokine production in macrophages.
Study Information
pubmed
2017
2017-01-16T00:00:00.000Z
10.1002/anie.201611685
48
60